Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHRSNASDAQ:KURANASDAQ:LRMRNASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$10.70+7.2%$10.27$6.00▼$20.50$519.24M0.86176,430 shs72,069 shsKURAKura Oncology$5.95+3.8%$6.44$5.41▼$23.48$515.12M0.51.18 million shs1.21 million shsLRMRLarimar Therapeutics$1.87+4.5%$2.21$1.61▼$11.20$119.73M0.93769,521 shs984,611 shsSTOKStoke Therapeutics$9.63+7.1%$8.12$5.35▼$17.58$525.77M1.2713,671 shs604,389 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research-0.80%-3.25%+9.79%-30.26%-23.35%KURAKura Oncology-1.21%+1.60%-2.05%-30.80%-72.60%LRMRLarimar Therapeutics-4.79%-17.51%-4.28%-45.26%-77.28%STOKStoke Therapeutics+0.67%+3.81%+18.92%-15.43%-29.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGHRSGH Research1.6706 of 5 stars3.51.00.00.01.92.50.0KURAKura Oncology4.2889 of 5 stars4.52.00.04.72.80.00.6LRMRLarimar Therapeutics2.4135 of 5 stars3.61.00.00.03.91.70.6STOKStoke Therapeutics3.702 of 5 stars3.60.00.04.83.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHRSGH Research 3.14Buy$30.43184.38% UpsideKURAKura Oncology 2.92Moderate Buy$23.89301.49% UpsideLRMRLarimar Therapeutics 3.10Buy$19.63949.47% UpsideSTOKStoke Therapeutics 3.29Buy$23.20140.91% UpsideCurrent Analyst Ratings BreakdownLatest LRMR, GHRS, STOK, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.005/13/2025GHRSGH ResearchCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025GHRSGH ResearchGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $29.005/9/2025GHRSGH ResearchHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/2/2025KURAKura OncologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.004/29/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.004/28/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/8/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$36.003/25/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHRSGH ResearchN/AN/AN/AN/AN/AN/AKURAKura Oncology$67.99M7.58N/AN/A$5.35 per share1.11LRMRLarimar TherapeuticsN/AN/AN/AN/A$1.86 per shareN/ASTOKStoke Therapeutics$36.56M14.38N/AN/A$3.57 per share2.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHRSGH Research-$35.59M-$0.79N/AN/AN/AN/A-20.29%-19.49%N/AKURAKura Oncology-$152.63M-$2.10N/AN/AN/AN/A-44.09%-39.57%N/ALRMRLarimar Therapeutics-$36.95M-$1.49N/AN/AN/AN/A-35.87%-32.37%N/ASTOKStoke Therapeutics-$104.70M-$1.68N/AN/AN/A-629.90%-54.45%-40.77%N/ALatest LRMR, GHRS, STOK, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GHRSGH Research-$0.61-$0.19+$0.42-$0.19N/AN/A5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A3/24/2025Q4 2024LRMRLarimar Therapeutics-$0.29-$0.45-$0.16-$0.45N/AN/A3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 million2/27/2025Q4 2024GHRSGH Research-$0.23-$0.17+$0.06-$0.17N/AN/A2/26/2025Q4 2024KURAKura Oncology-$0.65-$0.22+$0.43-$0.22$57.96 million$53.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHRSGH ResearchN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHRSGH ResearchN/A15.8315.83KURAKura Oncology0.0211.4711.47LRMRLarimar TherapeuticsN/A13.1013.10STOKStoke TherapeuticsN/A5.095.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHRSGH Research56.90%KURAKura OncologyN/ALRMRLarimar Therapeutics91.92%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipGHRSGH Research41.60%KURAKura Oncology6.40%LRMRLarimar Therapeutics4.50%STOKStoke Therapeutics11.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHRSGH Research1052.03 million30.38 millionOptionableKURAKura Oncology13086.58 million73.49 millionOptionableLRMRLarimar Therapeutics3064.03 million61.57 millionOptionableSTOKStoke Therapeutics10054.60 million46.98 millionOptionableLRMR, GHRS, STOK, and KURA HeadlinesRecent News About These CompaniesStoke Therapeutics (NASDAQ:STOK) Shares Gap Up Following Earnings BeatMay 15 at 10:35 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Strong EarningsMay 15 at 1:19 AM | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives $25.60 Consensus PT from BrokeragesMay 14 at 1:35 AM | americanbankingnews.comStoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue EstimatesMay 13 at 10:50 AM | zacks.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LPMay 13 at 3:22 AM | marketbeat.comGranahan Investment Management LLC Trims Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)May 12 at 6:35 AM | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from BrokeragesMay 12 at 2:35 AM | marketbeat.comDAFNA Capital Management LLC Has $1.89 Million Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)May 10, 2025 | marketbeat.comBaker BROS. Advisors LP Increases Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)May 6, 2025 | marketbeat.com291,795 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by Schonfeld Strategic Advisors LLCMay 6, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4% - Here's WhyApril 30, 2025 | marketbeat.comStoke Therapeutics (STOK) Projected to Post Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comRenaissance Technologies LLC Invests $1.42 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)April 30, 2025 | marketbeat.comStoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseApril 28, 2025 | zacks.comMarshall Wace LLP Sells 719,301 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)April 24, 2025 | marketbeat.comStoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?April 22, 2025 | zacks.comWhy Stoke Therapeutics, Inc.’s (STOK) Stock Is Up 8.32%April 22, 2025 | aaii.comStoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?April 22, 2025 | zacks.comFY2029 Earnings Estimate for STOK Issued By Leerink PartnrsApril 18, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Buy" by AnalystsApril 17, 2025 | marketbeat.comWhy Stoke Therapeutics, Inc.’s (STOK) Stock Is Up 7.69%April 15, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLRMR, GHRS, STOK, and KURA Company DescriptionsGH Research NASDAQ:GHRS$10.70 +0.72 (+7.21%) As of 04:00 PM EasternGH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.Kura Oncology NASDAQ:KURA$5.95 +0.22 (+3.84%) As of 04:00 PM EasternKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Larimar Therapeutics NASDAQ:LRMR$1.87 +0.08 (+4.47%) As of 04:00 PM EasternLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Stoke Therapeutics NASDAQ:STOK$9.63 +0.64 (+7.12%) As of 04:00 PM EasternStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
